Table 3.

Screening recommendations for patients with SUFU germline pathogenic variations

Tumours	Methods for screening	Surveillance recommendations in carriers of germline SUFU variants (periodicity, age to start and to end)
BCC	Dermatological examination	Annually beginning at age 20 years
		earlier if previous radiotherapy
Medulloblastoma	Brain MRI without contrast agent except for the first MRI	Every 3–4 months during the first 3 years then every 6 months until 5 years
Meningioma	Brain MRI	Every 3–5 years beginning at age 30 years for patients with no previous MB
		after healing of the MB in other patients
Ovarian tumour	Pelvic ultrasound	Every 3 years, beginning at age 5 years
Cardiac fibroma	Echocardiogram	At the time of diagnosis of GS, ideally in the first 6 months of life

BCC, basal cell carcinoma; GS, Gorlin syndrome; MB, medulloblastoma.